Department of Dermatology
Department of Pathology, Faculty of Medicine and Surgery
Diabetes and Endocrine Centre, Mater Dei Hospital, Msida, Malta
Faculty of Medicine and Surgery
Department of Dermatology, Hôpital Erasme, Universite Libre de Bruxelles, Bruxelles, Belgium
Department of Dermatology, Venereology and Leprosy; KPC Medical College & Hospital, Kolkata, India
Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia
Department of Dermatology, Liverpool Hospital, Sydney, NSW, Australia
University of New South Wales, Sydney, NSW, Australia
Faculty of Medicine and Surgery
Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta
Correspondence: Dillon Mintoff. Email: [email protected]
Conflicts of interest: D.M. has received research funding from: Bioderma, Avene, LEO Pharma, La Roche Posay. J.W.F. has conducted advisory work for Janssen, Boehringer-Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, AbbVie, Azora, Novartis and UCB, participated in trials for Pfizer, UCB, Boehringer-Ingelheim, Eli Lilly, CSL, Azora and received research support from Ortho Dermatologics, Sun Pharma, LEO Pharma, UCB and La Roche Posay. The other authors declare they have no conflicts of interest.
Received March 06, 2023
Received in revised form April 24, 2023
Accepted May 08, 2023
Revised July 06, 2023
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
